Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 25.
ZANTAC 150 vs ZANTAC 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits basal and stimulated gastric acid secretion by blocking H2 receptors on parietal cells in the stomach.
Competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells, reducing both basal and stimulated acid production.
150 mg orally twice daily or 300 mg orally once daily at bedtime.
Ranitidine 150 mg orally twice daily or 50 mg intravenously every 6-8 hours.
None Documented
None Documented
2.5 hours (range 1.5-3.5 h); prolonged in renal impairment (creatinine clearance <50 mL/min: 4-8 h).
Terminal elimination half-life: 2.5-3.0 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 6-8 hours in severe renal impairment (CrCl <30 mL/min).
Renal (70% unchanged via tubular secretion), biliary (30% as metabolites and unchanged drug).
Renal: 70% unchanged via tubular secretion; fecal: 30% as metabolites (N-oxide, S-oxide, desmethyl).
Category C
Category C
H2 Antagonist
H2 Antagonist